Another study revealed that, in glioma-bearing mice, a triple combination therapy, consisting anti-PD-1 immunotherapy and GVAX (a Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting allogeneic vaccine), or OX40 agonist immuno-therapy provided more survival rate when compared to each of these agents separately. This evidence concerns the gene CSF2 and glioma.